ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 Meeting Abstract
| Authors: | Bhatia, S.; Brohl, A. S.; Brownell, I.; Chandra, S.; Dakhil, S.; Ernstoff, M. S.; Fecher, L. A.; Gooley, T.; Hanna, G. J.; Hibbert, R.; Kelly, C. M.; Kiriluk, S. M.; Nghiem, P.; Nguyen, V.; Pelz, N.; Poisson, A. A.; Price, K. A. R.; Sondak, V. K.; Thompson, J. A.; Tykodi, S. S. |
| Abstract Title: | ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372 |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 515s |
| Language: | English |
| ACCESSION: | WOS:000442916008032 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.TPS9605 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS9605 -- Source: Wos |
